Posted July 2, 2012
Trial results boost potential GSK blockbuster respiratory drug
Research Triangle Park, N.C. —The drug to treat patients with chronic obstructive pulmonary disease under development could mean $3.5 billion or more a year in sales for Glaxo and replace its best-selling Advair, analysts say....Copyright 2013 WRAL Tech Wire. All rights reserved.
Please log in to view WRALTechWire Insider content
Please Log In to add a comment.